-
Je něco špatně v tomto záznamu ?
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
MM. Hoeper, G. Simonneau, PA. Corris, HA. Ghofrani, JR. Klinger, D. Langleben, R. Naeije, P. Jansa, S. Rosenkranz, L. Scelsi, E. Grünig, CD. Vizza, M. Chang, P. Colorado, C. Meier, D. Busse, RL. Benza,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
NLK
Free Medical Journals
od 1994 do Před 18 měsíci
Open Access Digital Library
od 1988-01-01
- MeSH
- antagonisté endotelinového receptoru terapeutické užití MeSH
- antihypertenziva škodlivé účinky terapeutické užití MeSH
- cévní rezistence účinky léků MeSH
- dospělí MeSH
- inhibitory fosfodiesterasy 5 terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- natriuretický peptid typu B krev MeSH
- peptidové fragmenty krev MeSH
- plicní hypertenze farmakoterapie mortalita patofyziologie MeSH
- prospektivní studie MeSH
- pyrazoly škodlivé účinky terapeutické užití MeSH
- pyrimidiny škodlivé účinky terapeutické užití MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- Světová zdravotnická organizace MeSH
- test chůzí MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
- Severní Amerika MeSH
A proportion of pulmonary arterial hypertension (PAH) patients do not reach treatment goals with phosphodiesterase-5 inhibitors (PDE5i). RESPITE investigated the safety, feasibility and benefit of switching from PDE5i to riociguat in these patients.RESPITE was a 24-week, open-label, multicentre, uncontrolled study. Patients in World Health Organization (WHO) functional class (FC) III, with 6-min walking distance (6MWD) 165-440 m, cardiac index <3.0 L·min-1·m-2 and pulmonary vascular resistance >400 dyn·s·cm-5 underwent a 1-3 day PDE5i treatment-free period before receiving riociguat adjusted up to 2.5 mg maximum t.i.d Exploratory end-points included change in 6MWD, WHO FC, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and safety.Of 61 patients enrolled, 51 (84%) completed RESPITE. 50 (82%) were receiving concomitant endothelin receptor antagonists. At week 24, mean±sd 6MWD had increased by 31±63 m, NT-proBNP decreased by 347±1235 pg·mL-1 and WHO FC improved in 28 patients (54%). 32 patients (52%) experienced study drug-related adverse events and 10 (16%) experienced serious adverse events (2 (3%) study drug-related, none during the PDE5i treatment-free period). Six patients (10%) experienced clinical worsening, including death in two (not study drug-related).In conclusion, selected patients with PAH may benefit from switching from PDE5i to riociguat, but this strategy needs to be further studied.
Centre for Pulmonary Hypertension Thorax Clinic at the University Hospital Heidelberg Germany
Chrestos Concept GmbH and Co KG Essen Germany
Clinic 3 for Internal Medicine University of Cologne Cologne Germany
Dept of Cardiology Erasme University Hospital Brussels Belgium
Global Clinical Development Bayer HealthCare Pharmaceuticals Barcelona Spain
Global Medical Affairs Bayer Pharma AG Berlin Germany
Institute of Cellular Medicine Newcastle University Newcastle upon Tyne UK
The Cardiovascular Institute Allegheny General Hospital Pittsburgh PA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024665
- 003
- CZ-PrNML
- 005
- 20180718102413.0
- 007
- ta
- 008
- 180709s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1183/13993003.02425-2016 $2 doi
- 035 __
- $a (PubMed)28889107
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Hoeper, Marius M $u Clinic for Respiratory Medicine, Hannover Medical School, member of the German Centre for Lung Research (DZL), Hannover, Germany Hoeper.Marius@mh-hannover.de.
- 245 10
- $a RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors / $c MM. Hoeper, G. Simonneau, PA. Corris, HA. Ghofrani, JR. Klinger, D. Langleben, R. Naeije, P. Jansa, S. Rosenkranz, L. Scelsi, E. Grünig, CD. Vizza, M. Chang, P. Colorado, C. Meier, D. Busse, RL. Benza,
- 520 9_
- $a A proportion of pulmonary arterial hypertension (PAH) patients do not reach treatment goals with phosphodiesterase-5 inhibitors (PDE5i). RESPITE investigated the safety, feasibility and benefit of switching from PDE5i to riociguat in these patients.RESPITE was a 24-week, open-label, multicentre, uncontrolled study. Patients in World Health Organization (WHO) functional class (FC) III, with 6-min walking distance (6MWD) 165-440 m, cardiac index <3.0 L·min-1·m-2 and pulmonary vascular resistance >400 dyn·s·cm-5 underwent a 1-3 day PDE5i treatment-free period before receiving riociguat adjusted up to 2.5 mg maximum t.i.d Exploratory end-points included change in 6MWD, WHO FC, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and safety.Of 61 patients enrolled, 51 (84%) completed RESPITE. 50 (82%) were receiving concomitant endothelin receptor antagonists. At week 24, mean±sd 6MWD had increased by 31±63 m, NT-proBNP decreased by 347±1235 pg·mL-1 and WHO FC improved in 28 patients (54%). 32 patients (52%) experienced study drug-related adverse events and 10 (16%) experienced serious adverse events (2 (3%) study drug-related, none during the PDE5i treatment-free period). Six patients (10%) experienced clinical worsening, including death in two (not study drug-related).In conclusion, selected patients with PAH may benefit from switching from PDE5i to riociguat, but this strategy needs to be further studied.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antihypertenziva $x škodlivé účinky $x terapeutické užití $7 D000959
- 650 _2
- $a antagonisté endotelinového receptoru $x terapeutické užití $7 D065128
- 650 _2
- $a Evropa $7 D005060
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a plicní hypertenze $x farmakoterapie $x mortalita $x patofyziologie $7 D006976
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a natriuretický peptid typu B $x krev $7 D020097
- 650 _2
- $a Severní Amerika $7 D009656
- 650 _2
- $a peptidové fragmenty $x krev $7 D010446
- 650 _2
- $a inhibitory fosfodiesterasy 5 $x terapeutické užití $7 D058986
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a pyrazoly $x škodlivé účinky $x terapeutické užití $7 D011720
- 650 _2
- $a pyrimidiny $x škodlivé účinky $x terapeutické užití $7 D011743
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a cévní rezistence $x účinky léků $7 D014655
- 650 _2
- $a test chůzí $7 D000070857
- 650 _2
- $a Světová zdravotnická organizace $7 D014944
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Simonneau, Gérald $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre, France.
- 700 1_
- $a Corris, Paul A $u Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
- 700 1_
- $a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Centre, member of the German Centre for Lung Research (DZL), Giessen, Germany. Dept of Medicine, Imperial College London, London, UK.
- 700 1_
- $a Klinger, James R $u Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA.
- 700 1_
- $a Langleben, David $u Centre for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada.
- 700 1_
- $a Naeije, Robert $u Dept of Cardiology, Erasme University Hospital, Brussels, Belgium.
- 700 1_
- $a Jansa, Pavel $u Clinical Dept of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Dept, Charles University, Prague, Czech Republic.
- 700 1_
- $a Rosenkranz, Stephan $u Clinic III for Internal Medicine (Cardiology), and Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. Cologne Cardiovascular Research Centre (CCRC), University of Cologne, Cologne, Germany.
- 700 1_
- $a Scelsi, Laura $u Division of Cardiology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy.
- 700 1_
- $a Grünig, Ekkehard $u Centre for Pulmonary Hypertension, Thorax Clinic at the University Hospital, Heidelberg, Germany.
- 700 1_
- $a Vizza, Carmine Dario $u Pulmonary Hypertension Unit, Dept of Cardiovascular and Respiratory Disease, 'La Sapienza' University of Rome, Rome, Italy.
- 700 1_
- $a Chang, MiKyung $u Global Medical Affairs, Bayer Pharma AG, Berlin, Germany.
- 700 1_
- $a Colorado, Pablo $u Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, Spain.
- 700 1_
- $a Meier, Christian $u Global Medical Affairs, Bayer Pharma AG, Berlin, Germany.
- 700 1_
- $a Busse, Dennis $u Chrestos Concept GmbH & Co. KG, Essen, Germany.
- 700 1_
- $a Benza, Raymond L $u The Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, USA.
- 773 0_
- $w MED00001660 $t The European respiratory journal $x 1399-3003 $g Roč. 50, č. 3 (2017)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28889107 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180718102713 $b ABA008
- 999 __
- $a ok $b bmc $g 1316796 $s 1021586
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 50 $c 3 $e 20170909 $i 1399-3003 $m The European respiratory journal $n Eur Respir J $x MED00001660
- LZP __
- $a Pubmed-20180709
